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The nucleoprotein genes of influenza virus A/Netherlands/018/94 (H3N2) and influenza virus B/Harbin/7/94
were cloned into the bacterial expression vector pMalC to yield highly purified recombinant influenza virus A
and B nucleoproteins. With these recombinant influenza nucleoproteins, enzyme-linked immunosorbent assays
(ELISAs) were developed for the detection of influenza virus A- and B-specific immunoglobulin A (IgA) and
IgG serum antibodies. Serum samples were collected at consecutive time points after the onset of clinical
symptoms from patients with confirmed influenza virus A or B infections. Nucleoprotein-specific IgA antibod-
ies were detected in 41.2% of influenza virus A-infected patients and in 66.7% of influenza virus B-infected
patients on day 6 after the onset of clinical symptoms. In serum samples taken on day 21 (influenza virus
A-infected patients) or day 28 (influenza virus B-infected patients), nucleoprotein-specific IgA antibodies could
be detected in 58.8 and 58.3% of influenza virus A- and B-infected patients, respectively. At the same time, IgG
antibody rises were detected in 88.2% of influenza virus A-infected patients and in 95.8% of influenza virus
B-infected patients. On comparison, hemagglutination inhibition assays detected antibody titer rises in 81.3
and 72.7% of patients infected with influenza viruses A and B, respectively. In contrast to the detection of
nucleoprotein-specific IgG antibodies or hemagglutination-inhibiting antibodies, the detection of nucleopro-
tein-specific IgA antibodies does not require paired serum samples and therefore can be considered an
attractive alternative for the rapid serological diagnosis of influenza.
Influenza viruses (family Orthomyxoviridae) are the causal
agents of recurrent epidemics of acute respiratory disease in
humans. For the laboratory diagnosis of influenza virus infec-
tions, several methods which detect either viral antigens or
antigen-specific serum antibodies are used. For the quantifica-
tion of influenza virus-specific serum antibodies, the hemag-
glutination inhibition (HI) assay and complement fixation (CF)
assay are routinely used. However, these assays suffer from
some disadvantages. They are laborious to perform, difficult to
incorporate into automated procedures, and require a contin-
uous source of the appropriate erythrocytes. Alternatively, en-
zyme-linked immunosorbent assays (ELISAs) have been used
for the detection of influenza virus-specific antibodies. ELISAs
measuring influenza virus-specific serum IgG antibodies have
been shown to be more sensitive than the HI or the CF assay
(1, 10, 11, 13–17, 22, 23). In addition, ELISAs enable the
detection of antibodies of different isotypes (3, 6, 18, 19). For
example, the demonstration of virus-specific IgA antibodies
after influenza virus infections has been shown to be of diag-
nostic value (5, 6, 19). The preparation of viral antigens to be
used in these ELISAs usually requires the concentration and
purification of virus conventionally propagated in embryo-
nated chicken eggs or cell culture. However, ELISAs with
purified (recombinant) viral proteins have also been described
(8, 9, 12, 20). In the present paper we describe the production
of recombinant nucleoproteins (NPs) of influenza viruses A
and B as a virtually unlimited source of viral antigen. By using
highly purified recombinant NPs of influenza viruses A and B,
ELISAs were developed for the detection of virus-specific im-
munoglobulin A (IgA) and IgG serum antibodies. With serum
samples obtained from patients with confirmed influenza virus
A and B infections, the value of these recombinant NP-based
ELISA systems was demonstrated.
MATERIALS AND METHODS
Cloning of the NP genes of influenza viruses A and B. The influenza viruses
A/Netherlands/018/94 (H3N2) and B/Harbin/7/94 were obtained from the repos-
itory of the Dutch National Influenza Centre. Viral RNA was extracted from
these viruses as described previously (4). A reverse transcriptase (RT) reaction
was performed to obtain single-stranded DNA copies of gene segment 5, which
encodes the NP. To 10 ml of viral RNA 2 ml of forward primer (10 pmol/ml) was
added and the mixture was incubated at 80°C for 2 min, followed by 5 min of
incubation on ice. Then, deoxynucleoside triphosphates (0.5 mM each), dithio-
threitol (10 mM), RNasin (40 units), and Moloney murine leukemia virus RT
(200 U) were added in a total volume of 25 ml of 13 RT buffer followed by
incubation at 42°C for 45 min. The reaction was stopped by heating the mixture
to 95°C for 3 min. The DNA obtained was used as a template in a PCR. Besides
the DNA, the PCR mixture contained 20 pmol of forward primer and 20 pmol
of reverse primer, deoxynucleoside triphosphates (0.2 mM each), and Pfu poly-
merase (5 units) in a total volume of 100 ml of 13 Pfu buffer. The PCR cycles
consisted of 1 min at 94°C, 2 min at 52°C, and 4 min at 72°C for a total of 40
cycles. Primer sequences were based on the consensus sequence of the NP genes
of recent influenza virus A and B strains obtained from the Wisconsin Sequence
Analysis Package and were designed in such a way that the ultimate PCR product
contained an EcoRI (influenza virus A) or XbaI (influenza virus B) restriction
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endonuclease recognition sequence upstream of the start codon and a SalI
restriction endonuclease recognition sequence downstream of the stop codon of
the NP genes. The PCR products of the NP genes of both viruses were cloned
into the bacterial expression vector pMalC (New England Biolabs) in frame with
the gene encoding the maltose binding protein (MBP) by using the EcoRI or
XbaI and SalI sites in the multiple cloning site of this plasmid. Restriction
endonuclease digestion, ligation, transformation in Escherichia coli DH5a, plas-
mid DNA isolation, and agarose gel electrophoresis were performed by standard
procedures (21).
Production, isolation, and purification of recombinant NP. A total of 500 ml
of SOB medium (21) containing ampicillin (50 mg/ml) and supplemented with
glucose (2 g/liter) was inoculated with 5 ml of an overnight culture of recombi-
nant E. coli, and the mixture was incubated at 37°C in a shaking incubator. The
optical density (OD) at a wavelength of 600 nm (OD600) was monitored, and at
an OD600 value of between 0.5 and 0.6, 1 mM isopropyl b-D-thiogalactopyrano-
side was added to induce expression of the fusion gene. Four hours after induc-
tion, the bacteria were pelleted by centrifugation, resuspended in 25 ml of
column buffer (20 mM Tris-HCl [pH 7.4], 200 mM NaCl, 1 mM EDTA) con-
taining Pefablock protease inhibitor (Boehringer Mannheim), and lysed by son-
ication. The lysate was diluted to 100 ml in column buffer and was run through
an amylose resin column (New England Biolabs). After extensive washing of the
column, recombinant protein was eluted with column buffer containing 25 mM
maltose. Peak fractions were pooled, and the purified proteins were stored at
270°C until use. Protein concentrations were determined by using the Bradford
reagent (2). The procedure was carried out for recombinant E. coli carrying the
pMalC plasmid without cloned sequences to obtain recombinant MBP (rMBP)
and for recombinant E. coli carrying the pMalC plasmid in which the NP gene of
influenza virus A or B was cloned to obtain recombinant fusion proteins con-
sisting of MBP and influenza virus A NP (rNPA) or influenza virus B NP (rNPB),
respectively.
SDS-PAGE and Western blotting. Sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) and Western blotting were performed by standard
procedures (21). Blots were incubated with blocking buffer (2% nonfat milk
powder, 0.05% Tween 20 in phosphate-buffered saline [PBS]) for 1 h, followed
by 1 h of incubation with 1:100-diluted polyclonal rabbit antisera specific for
influenza virus A or B. After washing of the blots with PBS, the blots were
incubated for 1 h with 1:500-diluted horseradish peroxidase (HRP)-labeled swine
anti-rabbit IgG antibodies (Dako, Glostrup, Denmark). Then, the blots were
washed with PBS followed by incubation in diaminobenzidine-H2O2 in PBS (250
mg of diaminobenzidine/ml, 0.002% H2O2). The reaction was stopped with H2O
when protein bands became visible.
Sera. Influenza virus A- and B-specific polyclonal rabbit and ferret antisera
were obtained from rabbits injected with sucrose gradient-purified influenza
virus A/Hong Kong/2/68 (H3N2) or B/Harbin/7/94 and from ferrets experimen-
tally infected with influenza virus A/Netherlands/018/94 (H3N2) or B/Harbin/7/
94.
Human sera were obtained from adult patients with acute influenza virus B
(n 5 24) and influenza virus A (H1N1; n 5 2, H3N2; n 5 15) infection; the
patients were enrolled in clinical studies during the respiratory season in March
1995 and December 1995, respectively. Influenza virus infection was confirmed
by an immunofluorescence test or by virus isolation from cell culture. Sera were
collected on the day of onset of clinical symptoms (day 1) and at several time
points thereafter. For the influenza virus A-infected patients, additional serum
samples collected on days 6, 21, and 60 were available. For the patients with
influenza virus B infection, additional serum samples collected on days 6 and 28
were available. Sera were stored at 220°C until use.
HI assay. One volume of serum was mixed with 5 volumes of cholera filtrate,
and the mixture was incubated at 37°C for approximately 16 h, followed by 1 h
of incubation at 56°C. To 50 ml of twofold dilution series of serum in PBS, 25 ml
of a solution of influenza virus A/Singapore/6/86 (H1N1), A/Johannesburg/33/94
(H3N2), or B/Harbin/7/94 containing 4 hemagglutinating units was added, and
the mixture was incubated at 37°C for 30 min. Then, 25 ml of a 1% turkey
erythrocyte suspension in PBS was added, followed by 1 h of incubation at 4°C.
Subsequently, the hemagglutination pattern was examined and was expressed as
the reciprocal value of the highest serum dilution inhibiting hemagglutination. A
fourfold titer rise for paired serum samples was considered indicative of a recent
influenza virus infection.
ELISA. (i) ELISA for detection of IgA serum antibodies (capture IgA NP
ELISA). Ninety-six-well plates coated with rabbit anti-human IgA antibodies
(Meddens Diagnostics, Brummen, The Netherlands) were washed with demin-
eralized H2O containing 0.05% Tween 80, followed by incubation with patient
sera diluted 1:100 in ELISA buffer (Meddens Diagnostics). After 1 h of incuba-
tion at 37°C, the plates were washed and incubated with rNPA or rNPB, which
were conjugated with HRP by previously described methods (24). Following 1 h
of incubation at 37°C, the plates were washed again and incubated with tetram-
ethylbenzidine substrate (Meddens Diagnostics) for 10 min. The reaction was
stopped with 2 M H2SO4, and the OD was measured at 450 nm. NP-specific
reactivities were expressed as the following ratio: OD450 for patient serum/OD450
for negative control serum. The negative control serum consisted of a pool of
sera negative for influenza virus A- and B-specific IgA antibodies. Ratios greater
than 2.0 were considered positive.
(ii) ELISA for detection of IgG serum antibodies (indirect IgG NP ELISA).
For rabbit and ferret sera, 96-well plates were coated overnight at room tem-
perature with 50 ng of rNPA or rNPB in 100 ml of 0.1 M sodium carbonate buffer
(pH 9.6). The plates were washed with demineralized H2O containing 0.05%
Tween 80. Influenza virus A- and B-specific rabbit and ferret antisera were
twofold diluted from 1:100 to 1:6,400 in ELISA buffer. A total of 50 ml of each
dilution was incubated in the recombinant NP-coated plates for 1 h at 37°C.
After washing of the plates, 50 ml of 1:500-diluted goat anti-ferret IgG antibodies
(Kirkegaard & Perry) or 1:500-diluted swine anti-rabbit IgG antibodies (Dako,
Glostrup, Denmark) conjugated with HRP was added, and the mixture was
incubated for 1 h at 37°C. The plates were washed again and were incubated with
50 ml of tetramethylbenzidine substrate for 10 min. The reaction was stopped by
adding 50 ml of 2 M H2SO4, and the OD450 was measured.
For human sera, ELISA was performed as described above. Human sera were
diluted 1:100,000, and IgG antibodies were detected with 1:5,000-diluted HRP-
labeled goat anti-human IgG antibodies (Biosource Europe, Fleurus, Belgium).
In addition to reactivities with rNPA and rNPB, the reactivity of human sera with
rMBP was also measured. NP-specific reactivities were expressed as the follow-
ing ratio: OD450 measured with rNPA or rNPB/OD450 measured with rMBP. An
increase in this ratio for paired serum samples of at least a factor 2.0 was
considered indicative of a recent influenza virus infection.
RESULTS
Recombinant NPs of influenza viruses A and B. After in-
duction of expression and purification by affinity chromatogra-
phy, the recombinant proteins rNPA and rNPB were analyzed
by SDS-PAGE. As shown in Fig. 1A, highly purified protein
preparations with molecular masses of 100 kDa for rNPA and
107 kDa for rNPB (including one of 40 kDa for MBP) were
obtained. The difference in the molecular masses between
rNPA and rNPB is in accordance with the difference in the
lengths of the coding sequences for both proteins (1,494 bp for
the NP of influenza virus A and 1,680 bp for the NP of influ-
enza virus B). The identities of rNPA and rNPB were con-
firmed by Western blot analysis. Rabbit antiserum raised
against an influenza virus A reacted only with rNPA and not
with rNPB, whereas a rabbit antiserum directed against an
influenza virus B showed reactivity with rNPB but not with
rNPA (Fig. 1B and C, respectively). The identities of the re-
combinant proteins were further confirmed in indirect ELISAs
with rabbit and ferret antisera raised against influenza viruses
A and B which showed reactivity only with the homologous
rNPA and rNPB, respectively (Fig. 2).
Detection of IgA antibodies in patient sera by capture IgA
NP ELISA. Serum samples collected at consecutive time points
from patients with confirmed influenza virus A and B infec-
FIG. 1. Analysis of rNPA and rNPB by SDS-PAGE and Western blotting.
rMBP (lane 1), rNPA (lane 2), and rNPB (lane 3) were separated on an SDS–
10% polyacrylamide gel and stained with Coomassie brilliant blue (A) or trans-
ferred to nitrocellulose membranes which were incubated with rabbit serum
specific for influenza virus A (B) or influenza virus B (C).
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tions were analyzed for the presence of NP-specific IgA anti-
bodies. For the group of patients infected with influenza virus
A, an IgA response against the NP of influenza virus A but not
that of influenza virus B was measured (Fig. 3A). The IgA
response peaked at day 21 and subsequently declined. Sera
from 10 of 17 patients (58.8%) showed reactivity with rNPA at
day 21, while serum from only 1 patient (5.9%) showed reac-
tivity with rNPB at this time point (Fig. 4A). For the group of
patients infected with influenza virus B, a type-specific IgA
response against NP was observed. The response showed a
peak 6 days after the onset of clinical symptoms and slowly
declined by day 28 (Fig. 3B). For this group of patients, sera
from two patients (8.3%) showed reactivity with rNPB on day
1 (Fig. 4B). This number increased until sera from 16 patients
(66.7%) showed reactivity by day 6. Sera from four patients
(16.7%) showed reactivity with rNPA on day 1, but this num-
ber did not increase during the course of infection.
Detection of IgG antibodies in patient sera by indirect IgG
NP ELISA. The same serum samples were also analyzed for
NP-specific IgG antibodies. For the group of patients infected
with influenza virus A, a type-specific IgG response against NP
was observed (Fig. 3C). No reactivity was measured with the
heterotypic rNPB. The NP-specific IgG response reached a
maximum at 21 days after the onset of clinical symptoms and
subsequently declined. For sera from 15 of 17 patients (88.2%)
an increase in reactivity with rNPA was observed on day 21,
whereas sera from none of these patients showed reactivity
with rNPB (Fig. 4A). In the influenza virus B-infected patients,
a strong IgG response against the homologous NP was ob-
served, and this response increased at least until day 28 after
the onset of clinical symptoms (Fig. 3D). For this group, sera
from 23 of 24 patients (95.8%) showed an increase in reactivity
with rNPB on day 28, while sera from only 3 patients (12.5%)
showed an increase in reactivity with rNPA (Fig. 4B). In ad-
dition to rNPA and rNPB, the reactivities of sera with rMBP
were also measured. The reactivity with rMBP did not change
during the time course of influenza virus A or B infection (data
not shown).
Comparison of the indirect IgG NP ELISA and the HI assay.
In the HI assay, 13 of 16 (81.3%) patients infected with influ-
enza virus A showed a fourfold rise in serum antibody titer
(between day 1 and day 21) against influenza virus A, while
88.2% showed an NP-specific IgG response (Fig. 4A). Three
patients who showed NP-specific IgG responses did not show a
titer rise in the HI assay, whereas in two patients a rise in the
HI assay titer was observed but no NP-specific IgG response
was observed. None of the influenza virus A-infected patients
showed an influenza virus B NP-specific IgG response, whereas
by the HI assay the serum of one patient showed a rise in titer
against influenza virus B. Among the patients infected with
influenza virus B, the sera of 16 of 22 (72.7%) patients showed
rises in titers against influenza virus B (between day 1 and day
28) by the HI assay, while the sera of 95.8% showed NP-
specific IgG responses (Fig. 4B). For five patients, IgG re-
sponses against NP were observed in the absence of at least
fourfold rises in titer by the HI assay. The serum of one patient
did not show an NP-specific IgG response and no rise in titer
by the HI assay. The sera of three patients showed influenza
virus A and B NP-specific IgG responses. Serum from one of
those three patients and sera from another two patients
showed rises in titer to influenza viruses A and B by the HI
assay.
DISCUSSION
In the present paper, recombinant NPs of influenza viruses
A and B were used for the development of ELISA systems
which can detect virus-specific IgA and IgG serum antibodies.
By using serum samples from laboratory animals experimen-
tally immunized with influenza viruses A and B and from
humans with confirmed influenza virus A or B infections, the
specificities of these ELISAs were confirmed. In the majority
FIG. 2. Confirmation of the identity of rNPA and rNPB in indirect IgG NP
ELISAs. Plates were coated with rNPA (A and C) or rNPB (B and D) and
incubated with ferret (A and B) or rabbit (C and D) antisera raised against
influenza virus A (solid circles) or influenza virus B (open circles).
FIG. 3. IgA (A and B) and IgG (C and D) responses in influenza virus
A-infected (A and C) or influenza virus B-infected (B and D) patients as mea-
sured by the capture IgA NP ELISAs and indirect IgG NP ELISAs with rNPA
(solid circles) and rNPB (open circles). In the capture IgA NP ELISAs, the
reactivities of sera with rNPA and rNPB were measured, and NP-specific reac-
tivities were expressed as the ratio OD450 for patient serum/OD450 for negative
control serum. In the indirect IgG NP ELISAs, the reactivities of sera with
rMBP, rNPA, and rNPB were measured, and NP-specific reactivities were ex-
pressed as the ratio OD450 measured for rNPA or rNPB/OD450 measured for
rMBP. The mean 6 standard error of the mean values for the influenza virus
A-infected (n 5 17) and influenza virus B-infected (n 5 24) patients at each time
point are presented.
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of the patients with influenza, virus type-specific antibodies
were detected, demonstrating the diagnostic value of these
recombinant NP-based ELISAs. These assays may replace the
commonly used HI and CF assays for the serodiagnosis of
influenza virus infections and can be performed when respira-
tory specimens are not available or to confirm results obtained
by culture procedures with respiratory specimens.
Capture IgA NP ELISAs were developed for the detection
of influenza virus A and B NP-specific IgA serum antibodies
with virus type-specific recombinant NP directly labeled with
HRP. IgA responses were detected within 21 days after the
onset of clinical symptoms in 58.8% of the influenza virus
A-infected patients and 66.7% of the influenza virus B-infected
patients. These percentages are comparable to the percentages
of patients with virus-specific IgA responses reported in other
studies (3, 6, 18). The sera of four patients with confirmed
influenza virus B infections had IgA antibodies directed to
influenza virus A from the first day of clinical onset onward.
These patients may have suffered from a recent infection with
an influenza A virus. Since influenza viruses of type A have
also circulated in the 1994 and 1995 influenza season, this is a
likely explanation. Since the level of preexisting influenza virus
NP-specific IgA antibody levels is low, the capture IgA NP
ELISAs do not require paired serum samples and, therefore,
allow rapid serodiagnosis of influenza virus infections. This
ELISA can be considered an alternative to assays that measure
IgG serum antibodies when only one serum sample is avail-
able.
In addition to the capture IgA NP ELISAs, virus type-spe-
cific recombinant NP was also used for the detection of influ-
enza virus A and B NP-specific IgG serum antibodies in indi-
rect IgG NP ELISAs. By these ELISAs, IgG antibody rises
could be detected in almost all of the influenza virus A- and
B-infected patients. Although in these ELISAs serum antibod-
ies were measured against influenza virus NP, while in the HI
assay serum antibodies directed against the hemagglutinin
were measured, the results of both assays were compared to
evaluate the diagnostic value of the IgG NP ELISAs. The
results of the IgG NP ELISAs for the detection of influenza
virus A-specific antibodies compared well with the results ob-
tained by the HI assay. The IgG NP ELISA for the measure-
ment of influenza virus B-specific antibodies, however, de-
tected a higher percentage of patients with increased antibody
titers than the HI assay, which is in agreement with the results
of earlier studies (2, 11, 14, 16, 17, 22, 23).
In contrast to antibodies of the IgA and IgG isotypes, the
diagnostic value of IgM antibodies in influenza virus infection
seems to be limited. Although the measurement of IgM re-
sponses has been shown to be of diagnostic value in primary
influenza virus infection (3, 18), IgA and IgG antibody re-
sponses predominate in influenza virus-infected patients (5, 7,
11). Therefore, the measurement of IgG and IgA antibody
responses is preferred for the serologic confirmation of influ-
enza virus infections.
The division of influenza A and B viruses is based on anti-
genic differences in the NPs and matrix proteins. Indeed, no
rises in influenza virus B NP-specific IgG antibody titers were
measured in the influenza virus A-infected patients. However,
rises in influenza virus A and B NP-specific IgG antibody titers
were measured in 12.5% of the influenza virus B-infected pa-
tients. A recent influenza virus A infection or simultaneous
infection with influenza viruses A and B may explain this ob-
servation.
Since the NP is well conserved within the influenza A vi-
ruses, the IgG NP ELISA enables the detection of antibodies
induced by influenza A viruses of both circulating subtypes
(H1N1 and H3N2). Furthermore, this assay does not require
the annual adjustment of the viral antigen preparations, in
contrast to the HI assay, which measures antibodies against the
highly variable hemagglutinin. Two of the influenza virus A-
infected patients seemed to be infected with an H1N1 virus
since in the HI assay only rises in titer against an H1N1 virus
were measured (data not shown). Rises in NP-specific IgG
antibody levels could be measured in these individuals, even
though the recombinant NP used in the IgG NP ELISA was
derived from an H3N2 virus.
Although the reactivities with MBP differed between pa-
tients, none of them showed increases in MBP-specific IgG
antibody levels during the time course after the infection.
Thus, it does not seem to be necessary to measure MBP anti-
body titers separately to be able to detect rises in the levels of
influenza virus-induced antibodies in the IgG NP ELISAs.
In conclusion, recombinant influenza virus NPs were pro-
duced in virtually unlimited quantities and were purified to a
FIG. 4. Percentages of influenza virus A-infected (A) or influenza virus B-infected (B) patients showing NP-specific antibody responses as measured by the capture
IgA NP ELISAs and indirect IgG NP ELISAs and percentages of infected patients showing titer rises by the HI assay. The results of the capture IgA NP ELISAs for
serum samples s1 (day 1), s2 (day 6), and s3 (day 21 for influenza virus A-infected patients and day 28 for influenza virus B-infected patients) are shown. For the indirect
IgG NP ELISAs, results for paired samples (serum samples s2 and s3 compared to serum sample s1) are shown. In the HI assays, serum sample s3 was compared to
serum sample s1. The sera were tested for influenza virus type A (solid bars) and influenza virus type B (open bars).
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high degree. These bacterially expressed viral antigens proved
to be valuable reagents for the development of ELISA systems
for the detection of virus-specific IgA and IgG antibodies
which can be used for the serodiagnosis of influenza virus type
A and B infections. Especially for the detection of NP-specific
IgA antibodies, the IgA NP ELISA proved to be valuable since
it allows early diagnosis and does not require paired serum
samples.
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